A Phase 2 interventional study of PRT064445/Rivaroxaban and Placebo/Rivaroxaban in Healthy Volunteers, sponsored by Portola Pharmaceuticals. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-22.
Sponsored by Portola Pharmaceuticals (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
A randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously administered PRT064445 after dosing to steady state with one of four direct/indirect factor Xa (fXa) inhibitors in healthy volunteers.
Portola Pharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.
First submitted before Portola Pharmaceuticals became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
210 mg andexanet IV bolus administered over 7 minutes (\~30 mg/min)
Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban
420 mg andexanet IV bolus administered over 14 minutes (\~30 mg/min)
Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban
600 mg andexanet IV bolus administered over 20 minutes (\~30 mg/min)
Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban
720 mg IV bolus administered over 24 minutes \[\~30 mg/min\] followed by 240 mg continuous IV infusion \[4 mg/min over 60 min)
Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban
800 mg IV bolus administered over 26.7 minutes \[\~30 mg/min\] followed by 960 mg continuous IV infusion \[8 mg/min over 120 min\]
Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban
Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.
Drug: Placebo
Drug pages: PRT064445 · Rivaroxaban
Also known as: Andexanet
Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration
Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)
Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration
Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration
Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.
Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration
Efficacy: Percent Change From Baseline in Unbound Rivaroaxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration
Unbound rivaroxaban concentrations was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Unbound plasma concentrations for rivaroxaban were determined by a rapid equilibrium dialysis method followed by Liquid Chromatography-Mass Spectometry assay.
Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration
Andexanet Maximum Observed Plasma Concentration (Cmax)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay.
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Time of Maximum Observed Plasma Concentration (Tmax)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Apparent Terminal Elimination Half-life (t1/2)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Total Systemic Clearance (CL)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach, calculated as Dose/AUC0-inf
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Total Volume of Distribution (Vss)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Subject recruitment occurred at investigative site in the US between March 2013 through April 2014
| Milestone | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Started | 16 | 6 | 6 | 6 | 6 | 8 |
| Completed | 15 | 5 | 5 | 6 | 6 | 5 |
| Not completed | 1 | 1 | 1 | 0 | 0 | 3 |
| Withdrew: Did not receive treatment | 1 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 | 1 |
Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)
| Percent change in anti-fXa activity | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration | 22.37 ± 42.247 | -18.09 ± 23.922 | -50.59 ± 22.056 | -75.26 ± 19.072 | -88.91 ± 6.098 | -92.72 ± 3.084 |
Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.
| Percent change in thrombin generation | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration | 14.00 ± 29.267 | 107.47 ± 48.977 | 167.67 ± 36.568 | 246.02 ± 135.387 | 513.85 ± 285.992 | 559.14 ± 288.258 |
Unbound rivaroxaban concentrations was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Unbound plasma concentrations for rivaroxaban were determined by a rapid equilibrium dialysis method followed by Liquid Chromatography-Mass Spectometry assay.
| Percent change in unbound apixaban conc. | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Efficacy: Percent Change From Baseline in Unbound Rivaroaxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration | -11 ± 11 | 34 ± 22 | 52 ± 18 | 75 ± 16 | 67 ± 24 | 80 ± 12 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay.
| ng/mL | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Andexanet Maximum Observed Plasma Concentration (Cmax) | NA ± NA | 50400 ± 12100 | 105000 ± 28500 | 110000 ± 7070 | 123000 ± 28900 | 161000 ± 40400 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach
| ng*hr/mL | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf ) | NA ± NA | 51400 ± 7520 | 111000 ± 35900 | 133000 ± 11500 | 216000 ± 41300 | 429000 ± 85300 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.
| hr | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Andexanet Time of Maximum Observed Plasma Concentration (Tmax) | NA (NA to NA) | 0.17 (0.16 to 0.41) | 0.36 (0.29 to 0.52) | 0.51 (0.39 to 0.83) | 0.56 (0.44 to 0.70) | 0.52 (0.49 to 0.73) |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.
| hr | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Andexanet Apparent Terminal Elimination Half-life (t1/2) | NA ± NA | 4.97 ± 0.74 | 3.91 ± 0.43 | 4.54 ± 1.65 | 6.47 ± 3.59 | 4.45 ± 0.58 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach, calculated as Dose/AUC0-inf
| L/hr | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Andexanet Total Systemic Clearance (CL) | NA ± NA | 4.15 ± 0.556 | 4.18 ± 1.51 | 4.53 ± 0.399 | 4.58 ± 0.837 | 4.23 ± 0.808 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.
| L | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Andexanet Total Volume of Distribution (Vss) | NA ± NA | 5.23 ± 1.09 | 4.65 ± 1.69 | 5.39 ± 0.546 | 4.17 ± 0.797 | 3.34 ± 1.20 |
Collected over ~7 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Module 2 Placebo | — | 0/15 (0%) | 12/15 (80%) |
| Module 2 (210 mg) | — | 0/6 (0%) | 4/6 (66.7%) |
| Module 2 (420 mg) | — | 0/6 (0%) | 3/6 (50%) |
| Module 2 (600 mg) | — | 0/6 (0%) | 5/6 (83.3%) |
| Module 2 (720 mg Bolus + 240 mg Infusion) | — | 0/6 (0%) | 5/6 (83.3%) |
| Module 2 (800 mg Bolus + 960 mg Infusion) | — | 0/6 (0%) | 5/6 (83.3%) |
| Event | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) |
|---|---|---|---|---|---|---|
| Infusion-related reactionInjury, poisoning and procedural complications | 1/15 | 1/6 | 2/6 | 2/6 | 3/6 | 2/6 |
| Post procedural haematomaInjury, poisoning and procedural complications | 3/15 | 0/6 | 1/6 | 0/6 | 2/6 | 0/6 |
| Dizziness posturalNervous system disorders | 2/15 | 0/6 | 1/6 | 2/6 | 1/6 | 0/6 |
| HeadacheNervous system disorders | 3/15 | 0/6 | 1/6 | 2/6 | 0/6 | 2/6 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 3/15 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Abdominal tendernessGastrointestinal disorders | 0/15 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| Dry mouthGastrointestinal disorders | 0/15 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| ToothacheGastrointestinal disorders | 0/15 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| Catheter site haemorrhageGeneral disorders | 0/15 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
48 subjects were enrolled in this study. Three subjects received rivaroxaban but were discontinued prior to receiving andexanet/placebo due to problems with the infusion pumps observed in prior subjects in the cohort and these subjects were replaced.
| Age, Continuous(years) | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 38.2 ± 6.69 | 35.7 ± 3.33 | 35.7 ± 9.07 | 34.2 ± 7.25 | 35.2 ± 5.04 | 32.9 ± 8.10 | 35.8 ± 6.79 |
| Sex: Female, Male(Participants) | Module 2 Placebo | Module 2 (210 mg) | Module 2 (420 mg) | Module 2 (600 mg) | Module 2 (720 mg Bolus + 240 mg Infusion) | Module 2 (800 mg Bolus + 960 mg Infusion) | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 0 | 1 | 4 | 0 | 1 | 9 |
| Male | 13 | 6 | 5 | 2 | 6 | 7 | 39 |
No study locations are listed for this record.
The record gives a start of Dec 2012, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PRT064445 · Rivaroxaban